| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 16714-0908-01 | 16714-0908 | Bleomycin | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Dec 1, 2018 | In Use | |
| 00054-0399-25 | 00054-0399 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov 11, 2020 | In Use | |
| 71205-0013-49 | 71205-0013 | DEXAMETHASONE | TaperDex 12-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 2, 2018 | In Use | |
| 63629-1579-08 | 63629-1579 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 5, 2009 | In Use | |
| 68387-0240-10 | 68387-0240 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 23, 2007 | In Use | |
| 16729-0130-53 | 16729-0130 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
| 61919-0995-07 | 61919-0995 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 1, 2015 | In Use | |
| 69784-0620-25 | 69784-0620 | Busulfan | MYLERAN | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Alkylsulfonate | Oral | Jun 30, 2022 | In Use | |
| 00078-0567-51 | 00078-0567 | Everolimus | Afinitor | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 31, 2009 | In Use | |
| 61958-1701-01 | 61958-1701 | Idelalisib | Zydelig | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Jul 23, 2014 | In Use | |
| 80425-0075-01 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 70095-0080-01 | 70095-0080 | ERIBULIN MESYLATE | ERIBULIN MESYLATE | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | May 15, 2025 | In Use | |
| 71335-9715-02 | 71335-9715 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 17, 2023 | In Use | |
| 52959-0127-11 | 52959-0127 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 12, 2003 | In Use | |
| 62756-0238-88 | 62756-0238 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2019 | In Use | |
| 61748-0304-11 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
| 68788-8418-03 | 68788-8418 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 11, 2023 | In Use | |
| 25021-0227-06 | 25021-0227 | Arsenic Trioxide | Arsenic Trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb 15, 2023 | In Use | |
| 71335-1772-02 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 29, 2021 | In Use | |
| 00781-3531-91 | 00781-3531 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 9, 2024 | In Use | |
| 71288-0151-95 | 71288-0151 | Docetaxel anhydrous | Docetaxel anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 24, 2018 | In Use | |
| 60687-0876-65 | 60687-0876 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 2, 2025 | In Use | ||
| 72789-0401-30 | 72789-0401 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 3, 2024 | In Use | |
| 00378-0315-93 | 00378-0315 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 72205-0284-92 | 72205-0284 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 24, 2024 | In Use |
Found 11765 results — Export these results
Home